US 12,351,614 B2
CLEC9A-based chimeric protein complexes
Nikolai Kley, Waltham, MA (US); Erik Depla, Zwijnaarde (BE); Lennart Zabeau, Zwijnaarde (BE); and Jan Tavernier, Zwijnaarde (BE)
Assigned to Orionis Biosciences, Inc., Waltham, MA (US); and Orionis Biosciences BV, Zwijnaarde (BE)
Appl. No. 17/598,573
Filed by Orionis Biosciences, Inc., Waltham, MA (US); and Orionis Biosciences BV, Zwijnaarde (BE)
PCT Filed Mar. 27, 2020, PCT No. PCT/US2020/025423
§ 371(c)(1), (2) Date Sep. 27, 2021,
PCT Pub. No. WO2020/198662, PCT Pub. Date Oct. 1, 2020.
Claims priority of provisional application 62/906,442, filed on Sep. 26, 2019.
Claims priority of provisional application 62/825,584, filed on Mar. 28, 2019.
Prior Publication US 2022/0153801 A1, May 19, 2022
Int. Cl. C07K 14/56 (2006.01); A61K 38/00 (2006.01); A61P 35/00 (2006.01); C07K 14/00 (2006.01)
CPC C07K 14/56 (2013.01) [A61P 35/00 (2018.01); C07K 14/001 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)] 5 Claims
 
1. A chimeric protein complex comprising:
(i) a targeting moiety that specifically binds to C-type lectin domain family 9 member A (Clec9A),
(ii) a modified human IFNα2, and
(iii) a modified Fc domain,
wherein the chimeric protein complex comprises a polypeptide having the amino acid sequence of SEQ ID NO: 2 and further comprises a polypeptide having the amino acid sequence of SEQ ID NO: 7.